POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Novartis

Status and phase: Completed; Phase 2

Conditions: Relapsing-remitting Multiple Sclerosis; RRMS

Treatments: Drug: AIN457; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01051817

2009-011626-34

CAIN457B2201

Details and patient eligibility

About

A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis

Enrollment: 73 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

73 participants in 2 patient groups, including a placebo group

AIN457

Experimental group

Treatment:

Drug: AIN457

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo